Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | STAT6 | P42226 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7894673 | 1.00 | RAB9A (0.58) | RAB9ALMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7431601 | 0.95 | ALDH1A1 (0.59) | RAB9ALMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7431607 | 0.95 | ALDH1A1 (0.59) | RAB9ALMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL26550162 | 0.90 | RAB9A (0.65) | RAB9ALMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL10339541 | 0.85 | GAA (0.54) | RAB9ALMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL10339540 | 0.85 | GAA (0.54) | RAB9ALMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL26550187 | 0.81 | CYP1A2 (0.53) | RAB9ALMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL26550369 | 0.81 | GPR183 (0.50) | RAB9ALMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7436369 | 0.81 | MAPT (0.60) | RAB9ALMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7436371 | 0.81 | MAPT (0.60) | RAB9ALMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8239322-A | — | — | None | — | — | JP | disclosed |
| US-20230330097-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS LLC (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330097-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS LLC (US) | 2023-10-19 | — | — | US | disclosed |
| CN-101007776-A | Preparation process for N-substituted acryl lactam analog compound | UNIV ZHEJIANG TECHNOLOGY (CN) | 2007-08-01 | — | — | CN | disclosed |
| US-6180355-B1 | Method for diagnosing and treating chronic pelvic pain syndrome | UNIVERSITY OF MARYLAND, BALTIMORE | 2001-01-30 | — | — | US | disclosed |
| US-5753691-A | ADMINISTERING 1-CINNAMOYL-2-PYRROLIDINONE (OR DERIVATIVES) TO SUPPRESS INTERLEUKINS OR TUMOR NECROSIS FACTOR IN TREATMENT OF CHRONIC RHEUMATISM OR SEPSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5753691-A | ADMINISTERING 1-CINNAMOYL-2-PYRROLIDINONE (OR DERIVATIVES) TO SUPPRESS INTERLEUKINS OR TUMOR NECROSIS FACTOR IN TREATMENT OF CHRONIC RHEUMATISM OR SEPSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0720849-B1 | Agents for prevention or treatment of chronic rheumatism and sepsis | NISSHIN FLOUR MILLING CO (JP) | 1998-04-01 | — | — | EP | disclosed |
| JP-H08239322-A | MEDICINE COMPOSITION CONTAINING PYRROLIDINONE DERIVATIVE | NISSHIN FLOUR MILLING CO LTD | 1996-09-17 | — | — | JP | disclosed |
| EP-0720849-A3 | Agents for inhibiting the production of IL-1beta and the release of TNFalpha | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1996-07-17 | — | — | EP | disclosed |
| EP-0720849-A2 | Agents for inhibiting the production of IL-1beta and the release of TNFalpha | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1996-07-10 | — | — | EP | disclosed |
| EP-0720849-A2 | Agents for inhibiting the production of IL-1beta and the release of TNFalpha | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1996-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330097-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | EPDR1, HYOU1, MYOC | RAB9A 4093/4885LMNA 1196/4885MEN1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.